Swiss drugmaker Roche said on Sunday it expects to be able to produce “significantly more” than 100 million of its new antibody tests monthly by the end of 2020, doubling its current production.
Roche earlier on Sunday received an emergency use authorization from the U.S. Food and Drug Administration approving its test, which relies on taking intravenous blood samples to identify whether someone has previously been infected with the coronavirus and whether they have the antibodies to defend against it.
Roche said its Elecsys Anti-SARS-CoV-2 antibody test has a specificity greater than 99.8%, meaning very few false-positive tests, and that it can help assess people’s immune response to the virus. The company said it has already started shipping the new antibody test to top laboratories globally.
The best of the Muslim Times’ collection for war against Covid 19:
In this day and age, understanding bacteria and viruses and developing vaccines are national security issues. In my view sizable part of every country’s defense budget should be spent in these pursuits rather than making tanks and other weapons.